Curated News
By: NewsRamp Editorial Staff
October 26, 2026
PolyPeptide Shareholders Approve Board Changes and Tender Offer Conditions
TLDR
- Samsung Biologics gains a peptide CDMO foothold as PolyPeptide shareholders approve board changes and remove transfer restrictions.
- PolyPeptide shareholders elected a new board and removed transfer and voting limits, effective upon Samsung Peptide AG's tender offer settlement.
- PolyPeptide's expanded peptide manufacturing under Samsung Biologics could improve global access to therapies for metabolic diseases like GLP-1.
- PolyPeptide's shareholder meeting cleared the way for Samsung Biologics' tender offer by electing a new board and removing ownership restrictions.
Impact - Why it Matters
This news matters because it signals a major ownership transition for PolyPeptide, a key player in the peptide CDMO space, which could impact the supply chain for peptide-based therapies, including GLP-1 drugs. For investors, the removal of transfer restrictions and voting limitations may increase liquidity and facilitate the tender offer, potentially leading to a change of control. For the broader biotech and pharma industry, Samsung Biologics’ expansion into peptide manufacturing through this acquisition could intensify competition and drive innovation in a fast-growing market. Patients relying on peptide-based treatments may benefit from increased manufacturing capacity and investment.
Summary
PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that shareholders approved all board proposals at its extraordinary general meeting held on October 26, 2026, in Baar, Switzerland. The approvals mark a significant step toward the completion of a public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide. Shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as new Board members, with John Chongbo Rim appointed as chair. Cheol Woo Ryu and Seungho Ryu were also elected to the Remuneration and Nomination Committee. All elections are effective upon settlement of the Samsung Peptide offer.
In addition, shareholders resolved to remove the transfer restrictions (Vinkulierung) and voting limitations (Stimmrechtsbeschränkungen) from PolyPeptide’s articles of association, conditional on the satisfaction or waiver of all offer conditions in the Offer Prospectus dated 31 August 2026, except for the condition in section B.7.1(e). This move is expected to facilitate the tender offer and streamline the company’s share transfer regime. The original release can be viewed on www.newmediawire.com, and further details about PolyPeptide are available at polypeptide.com. The company also invites stakeholders to follow it on LinkedIn for updates.
PolyPeptide, founded in 1952, operates six GMP-certified facilities across Europe, the U.S. and India, providing products and services from pre-pre-clinical to commercial stages, with significant exposure to metabolic diseases including GLP-1. The shareholder decisions are a crucial milestone for the Samsung Biologics subsidiary’s tender offer and could reshape PolyPeptide’s ownership structure, potentially accelerating its growth in the peptide-based active pharmaceutical ingredients market.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, PolyPeptide Shareholders Approve Board Changes and Tender Offer Conditions
